{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:34:52Z","timestamp":1789900492075,"version":"4.0.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,4,23]],"date-time":"2009-04-23T00:00:00Z","timestamp":1240444800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Impot Res"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1038\/ijir.2009.11","type":"journal-article","created":{"date-parts":[[2009,4,23]],"date-time":"2009-04-23T08:32:52Z","timestamp":1240475572000},"page":"149-157","source":"Crossref","is-referenced-by-count":21,"title":["Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors"],"prefix":"10.1038","volume":"21","author":[{"given":"H","family":"Al-Ameri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R A","family":"Kloner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,4,23]]},"reference":[{"key":"BFijir200911_CR1","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1056\/NEJM200006153422407","volume":"342","author":"TF Lue","year":"2000","unstructured":"Lue TF . Erectile dysfunction. N Engl J Med 2000; 342: 1802\u20131813.","journal-title":"N Engl J Med"},{"key":"BFijir200911_CR2","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJM199805143382001","volume":"338","author":"I Goldstein","year":"1998","unstructured":"Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA . Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338: 1397\u20131404.","journal-title":"N Engl J Med"},{"key":"BFijir200911_CR3","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S0735-1097(00)00790-7","volume":"36","author":"SD Katz","year":"2000","unstructured":"Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S . Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000; 36: 845\u2013851.","journal-title":"J Am Coll Cardiol"},{"key":"BFijir200911_CR4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.eururo.2004.10.002","volume":"47","author":"GM Rosano","year":"2005","unstructured":"Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G . Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005; 47: 214\u2013220.","journal-title":"Eur Urol"},{"key":"BFijir200911_CR5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/sj.ijir.3901513","volume":"19","author":"A Aversa","year":"2007","unstructured":"Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G . Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res 2007; 19: 200\u2013207.","journal-title":"Int J Impot Res"},{"key":"BFijir200911_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/sj.ijir.3901454","volume":"18","author":"E Mazo","year":"2006","unstructured":"Mazo E, Gamidov S, Iremashvili V . The effect of vardenafil on endothelial function of brachial and cavernous arteries. Int J Impot Res 2006; 18: 464\u2013469.","journal-title":"Int J Impot Res"},{"key":"BFijir200911_CR7","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1038\/sj.ijir.3901425","volume":"17","author":"KL Billups","year":"2005","unstructured":"Billups KL . Erectile dysfunction as an early sign of cardiovascular disease. Int J Impot Res 2005; 17: S19\u2013S24.","journal-title":"Int J Impot Res"},{"key":"BFijir200911_CR8","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/ijir.2008.20","volume":"20","author":"RA Kloner","year":"2008","unstructured":"Kloner RA . Erectile dysfunction as a predictor of cardiovascular disease. Int J Impot Res 2008; 20: 460\u2013465.","journal-title":"Int J Impot Res"},{"key":"BFijir200911_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/sj.ijir.3901309","volume":"17","author":"R Kloner","year":"2005","unstructured":"Kloner R, Padma-Nathan H . Erectile dysfunction in patients with coronary artery disease. Int J Impot Res 2005; 17: 209\u2013215.","journal-title":"Int J Impot Res"},{"key":"BFijir200911_CR10","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/sj.ijir.3901527","volume":"19","author":"R Kloner","year":"2007","unstructured":"Kloner R . Erectile dysfunction and hypertension. Int J Impot Res 2007; 19: 296\u2013302.","journal-title":"Int J Impot Res"},{"key":"BFijir200911_CR11","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1038\/sj.ijir.3901426","volume":"17","author":"S Rastogi","year":"2005","unstructured":"Rastogi S, Rodriguez JJ, Kapur V, Schwarz ER . Why do patients with heart failure suffer from erectile dysfunction? A critical review and suggestions on how to approach this problem. Int J Impot Res 2005; 17: S25\u2013S36.","journal-title":"Int J Impot Res"},{"key":"BFijir200911_CR12","first-page":"e25","volume":"117","author":"W Rosamond","year":"2008","unstructured":"Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N et al. Heart disease and stroke statistics\u20142008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25\u2013146.","journal-title":"Circulation"},{"key":"BFijir200911_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S0022-5347(17)34871-1","volume":"151","author":"HA Feldman","year":"1994","unstructured":"Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB . Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54\u201361.","journal-title":"J Urol"},{"key":"BFijir200911_CR14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0147-9563(96)80061-6","volume":"25","author":"T Jaarsma","year":"1996","unstructured":"Jaarsma T, Dracup K, Walden J, Stevenson LW . Sexual function in patients with advanced heart failure. Heart Lung 1996; 25: 262\u2013270.","journal-title":"Heart Lung"},{"key":"BFijir200911_CR15","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/ijir.2008.35","volume":"20","author":"K Herbert","year":"2008","unstructured":"Herbert K, Lopez B, Castellano J, Palacio A, Tamari L, Arcemen LM . The prevalence of erectile dysfunction in heart failure patients by race and ethnicity. Int J Impot Res 2008; 20: 507\u2013511.","journal-title":"Int J Impot Res"},{"key":"BFijir200911_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/sj.ijir.3901613","volume":"20","author":"ER Schwarz","year":"2008","unstructured":"Schwarz ER, Kapur V, Bionat S, Rastogi S, Gupta R, Rosanio S . The prevalence and clinical relevance of sexual dysfunction in women and men with chronic heart failure. Int J Impot Res 2008; 20: 85\u201391.","journal-title":"Int J Impot Res"},{"key":"BFijir200911_CR17","doi-asserted-by":"publisher","first-page":"41F","DOI":"10.1016\/S0002-9149(00)00892-4","volume":"86","author":"I Goldstein","year":"2000","unstructured":"Goldstein I . The mutually reinforcing triad of depressive symptoms, cardiovascular disease, and erectile dysfunction. Am J Cardiol 2000; 86: 41F\u201345F.","journal-title":"Am J Cardiol"},{"key":"BFijir200911_CR18","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.jacc.2006.05.052","volume":"48","author":"ER Schwarz","year":"2006","unstructured":"Schwarz ER, Rastogi S, Kapur V, Sulemanjee N, Rodriguez JJ . Erectile dysfunction in heart failure patients. J Am Coll Cardiol 2006; 48: 1111\u20131119.","journal-title":"J Am Coll Cardiol"},{"key":"BFijir200911_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/01.HYP.29.1.8","volume":"29","author":"RH Grimm Jr","year":"1997","unstructured":"Grimm Jr RH, Grandits GA, Prineas RJ, McDonald RH, Lewis CE, Flack JM et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997; 29: 8\u201314.","journal-title":"Hypertension"},{"key":"BFijir200911_CR20","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1097\/00005392-199805000-00033","volume":"159","author":"S Gupta","year":"1998","unstructured":"Gupta S, Salimpour P, Saenz de Tejada I, Daley J, Gholami S, Baller M et al. A possible mechanism for alteration of human erectile function by digoxin: inhibition of corpus cavernosum sodium\/potassium adenosine triphosphate activity. J Urol 1998; 159: 1529\u20131536.","journal-title":"J Urol"},{"key":"BFijir200911_CR21","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/j.1464-410X.2008.07536.x","volume":"102","author":"H Muguruma","year":"2008","unstructured":"Muguruma H, Kawanishi Y, Sugiyama H, Kagawa J, Tanimoto S, Yamanaka M et al. Effect of aldosterone on isolated human penile corpus cavernosum tissue. BJU Int 2008; 102: 500\u2013503.","journal-title":"BJU Int"},{"key":"BFijir200911_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1440-1681.2007.04551.x","volume":"34","author":"K Brixius","year":"2007","unstructured":"Brixius K, Middeke M, Lichtenthal A, Jahn E, Schwinger RHG . Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol 2007; 34: 327\u2013331.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"BFijir200911_CR23","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/ijir.2008.28","volume":"20","author":"M Baumh\u00e4kel","year":"2008","unstructured":"Baumh\u00e4kel M, Schlimmer N, B\u00f6hm M . Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome. Int J Impot Res 2008; 20: 493\u2013500.","journal-title":"Int J Impot Res"},{"key":"BFijir200911_CR24","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1159\/000082598","volume":"24","author":"JE Toblli","year":"2004","unstructured":"Toblli JE, Stella I, Mazza ON, Ferder L, Inserra F . Different effect of losartan and amlodipine on penile structures in male spontaneously hypertensive rats. Am J Nephrol 2004; 24: 614\u2013623.","journal-title":"Am J Nephrol"},{"key":"BFijir200911_CR25","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.amjhyper.2006.05.016","volume":"19","author":"JE Toblli","year":"2006","unstructured":"Toblli JE, Cao G, Casas G, Mazza ON . In vivo and in vitro effects of nebivolol on penile structures in hypertensive rats. Am J Hypertens 2006; 19: 1226\u20131232.","journal-title":"Am J Hypertens"},{"key":"BFijir200911_CR26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.amjcard.2005.03.065","volume":"96","author":"JB Kostis","year":"2005","unstructured":"Kostis JB, Jackson G, Rosen R, Barrett-Connor E, Billups K, Burnett AL et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005; 96: 313\u2013321.","journal-title":"Am J Cardiol"},{"key":"BFijir200911_CR27","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.4065\/82.10.1203","volume":"82","author":"SA Mandras","year":"2007","unstructured":"Mandras SA, Uber PA, Mehra MR . Sexual activity and chronic heart failure. Mayo Clin Proc 2007; 82: 1203\u20131210.","journal-title":"Mayo Clin Proc"},{"key":"BFijir200911_CR28","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0002-9343(01)01119-6","volume":"112","author":"B Cremers","year":"2002","unstructured":"Cremers B, Kjellstrom B, Sudkamp M, Bohm M . Hemodynamic monitoring during sexual intercourse and physical exercise in a patient with chronic heart failure and pulmonary hypertension (letter). Am J Med 2002; 112: 428\u2013430.","journal-title":"Am J Med"},{"key":"BFijir200911_CR29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.amjcard.2004.08.060","volume":"95","author":"SD Katz","year":"2005","unstructured":"Katz SD, Parker JD, Glasser DB, Bank AJ, Sherman N, Wang H et al. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. Am J Cardiol 2005; 95: 36\u201342.","journal-title":"Am J Cardiol"},{"key":"BFijir200911_CR30","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1001\/archinte.164.5.514","volume":"164","author":"LJ Webster","year":"2004","unstructured":"Webster LJ, Michelakis ED, Davis T, Archer SL . Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial. Arch Intern Med 2004; 164: 514\u2013520.","journal-title":"Arch Intern Med"},{"key":"BFijir200911_CR31","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/sj.ijir.3901385","volume":"18","author":"D Freitas","year":"2006","unstructured":"Freitas D, Athanazio R, Almeida D, Dantas N, Reis F . Sildenafil improves quality of life in men with heart failure and erectile dysfunction. Int J Impot Res 2006; 18: 210\u2013212.","journal-title":"Int J Impot Res"},{"key":"BFijir200911_CR32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0735-1097(98)00656-1","volume":"33","author":"MD Cheitlin","year":"1999","unstructured":"Cheitlin MD, Hutter Jr. AM, Brindis RG, Ganz P, Kaul S, Russell RO et al. ACC\/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology\/American Heart Association. J Am Coll Cardiol 1999; 33: 273\u2013282.","journal-title":"J Am Coll Cardiol"},{"key":"BFijir200911_CR33","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1161\/01.CIR.0000146906.42375.D3","volume":"110","author":"RA Kloner","year":"2004","unstructured":"Kloner RA . Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004; 110: 3149\u20133155.","journal-title":"Circulation"},{"key":"BFijir200911_CR34","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.jacc.2003.09.023","volume":"42","author":"RA Kloner","year":"2003","unstructured":"Kloner RA, Hutter AM, Emmick JT, Mitchell MI, Denne J, Jackson G . Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003; 42: 1855\u20131860.","journal-title":"J Am Coll Cardiol"},{"key":"BFijir200911_CR35","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1161\/01.CIR.0000027149.83473.B6","volume":"106","author":"EA Bocchi","year":"2002","unstructured":"Bocchi EA, Guimaraes G, Mocelin A, Bacal F, Bellotti G, Ramires JF . Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002; 106: 1097\u20131103.","journal-title":"Circulation"},{"key":"BFijir200911_CR36","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.amjcard.2005.06.091","volume":"96","author":"K Hirata","year":"2005","unstructured":"Hirata K, Adji A, Vlachopoulos C, O'Rourke MF . Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol 2005; 96: 1436\u20131440.","journal-title":"Am J Cardiol"},{"key":"BFijir200911_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1161\/CIRCULATIONAHA.106.626226","volume":"115","author":"GD Lewis","year":"2007","unstructured":"Lewis GD, Lachmann J, Camuso J, Lepore JJ, Shin J, Martinovic ME et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007; 115: 59\u201366.","journal-title":"Circulation"},{"key":"BFijir200911_CR38","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.ejheart.2006.03.007","volume":"8","author":"A Al-Hesayen","year":"2006","unstructured":"Al-Hesayen A, Floras JS, Parker JD . The effects of intravenous sildenafil on hemodynamics and cardiac sympathetic activity in chronic human heart failure. Eur J Heart Fail 2006; 8: 864\u2013868.","journal-title":"Eur J Heart Fail"},{"key":"BFijir200911_CR39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cardfail.2007.11.006","volume":"14","author":"A Behling","year":"2008","unstructured":"Behling A, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N . Effects of 5\u2032-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Card Fail 2008; 14: 189\u2013197.","journal-title":"J Card Fail"},{"key":"BFijir200911_CR40","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/j.jacc.2007.07.078","volume":"50","author":"M Guazzi","year":"2007","unstructured":"Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD . Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007; 50: 2136\u20132144.","journal-title":"J Am Coll Cardiol"},{"key":"BFijir200911_CR41","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1161\/CIRCULATIONAHA.107.716373","volume":"116","author":"GD Lewis","year":"2007","unstructured":"Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116: 1555\u20131562.","journal-title":"Circulation"},{"key":"BFijir200911_CR42","first-page":"9","volume":"9","author":"SD Katz","year":"2003","unstructured":"Katz SD . Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure. CHF 2003; 9: 9\u201315.","journal-title":"CHF"},{"key":"BFijir200911_CR43","first-page":"1352","volume-title":"Textbook of Cardiovascular Medicine","author":"S Iyengar","year":"2007","unstructured":"Iyengar S, Haas GJ, Young JB . Acute heart failure. In: Topol EJ (ed). Textbook of Cardiovascular Medicine 3rd edn. Lippincott Williams & Wilkins: Philadelphia, 2007, pp 1352\u20131372."},{"key":"BFijir200911_CR44","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/0002-9343(78)90700-3","volume":"65","author":"DT Mason","year":"1978","unstructured":"Mason DT . Afterload reduction and cardiac performance. Physiologic basis of systemic vasodilators as a new approach in treatment of congestive heart failure. Am J Med 1978; 65: 106\u2013125.","journal-title":"Am J Med"},{"key":"BFijir200911_CR45","doi-asserted-by":"publisher","first-page":"3C","DOI":"10.1016\/S0002-9149(99)00042-9","volume":"83","author":"RM Wallis","year":"1999","unstructured":"Wallis RM, Corbin JD, Francis SH, Ellis P . Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999; 83: 3C\u201312C.","journal-title":"Am J Cardiol"},{"key":"BFijir200911_CR46","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1161\/CIRCULATIONAHA.106.655266","volume":"116","author":"J Nagendran","year":"2007","unstructured":"Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007; 116: 238\u2013248.","journal-title":"Circulation"},{"key":"BFijir200911_CR47","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1161\/CIRCULATIONAHA.108.822072","volume":"119","author":"P Pokreisz","year":"2009","unstructured":"Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, Busch C et al. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 2009; 119: 408\u2013416.","journal-title":"Circulation"},{"key":"BFijir200911_CR48","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1161\/CIRCULATIONAHA.105.540500","volume":"112","author":"BA Borlaug","year":"2005","unstructured":"Borlaug BA, Melenovsky V, Marhin T, Fitzgerald P, Kass DA . Sildenafil inhibits \u03b2-adrenergic-stimulated cardiac contractility in humans. Circulation 2005; 112: 2642\u20132649.","journal-title":"Circulation"},{"key":"BFijir200911_CR49","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nm1175","volume":"11","author":"E Takimoto","year":"2005","unstructured":"Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005; 11: 214\u2013222.","journal-title":"Nat Med"},{"key":"BFijir200911_CR50","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1056\/NEJMoa050010","volume":"353","author":"N Gali\u00e8","year":"2005","unstructured":"Gali\u00e8 N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148\u20132157.","journal-title":"N Engl J Med"},{"key":"BFijir200911_CR51","first-page":"1488","volume":"44","author":"HA Ghofrani","year":"2004","unstructured":"Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadas B et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004; 44: 1488\u20131496.","journal-title":"J Am Coll Cardiol"},{"key":"BFijir200911_CR52","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1291\/hypres.29.123","volume":"29","author":"K Aizawa","year":"2006","unstructured":"Aizawa K, Hanaoka T, Kasai H, Kogashi K, Kumazaki S, Koyama J et al. Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension. Hypertens Res 2006; 29: 123\u2013128.","journal-title":"Hypertens Res"},{"key":"BFijir200911_CR53","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ijcard.2005.08.051","volume":"108","author":"F Affuso","year":"2006","unstructured":"Affuso F, Palmieri EA, Di CP, Guardasole V, Fazio S . Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension. Int J Cardiol 2006; 108: 429\u2013431.","journal-title":"Int J Cardiol"},{"key":"BFijir200911_CR54","first-page":"52","volume":"58","author":"TS Singh","year":"2006","unstructured":"Singh TS, Kumar D, Basu S, Panja M, Mitra B . Tadalafil in the management of severe pulmonary artery hypertension. Indian Heart J 2006; 58: 52\u201353.","journal-title":"Indian Heart J"}],"container-title":["International Journal of Impotence Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ijir200911.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ijir200911","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ijir200911.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:17:30Z","timestamp":1684430250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ijir200911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,23]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["BFijir200911"],"URL":"https:\/\/doi.org\/10.1038\/ijir.2009.11","relation":{},"ISSN":["0955-9930","1476-5489"],"issn-type":[{"value":"0955-9930","type":"print"},{"value":"1476-5489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,23]]}}}